Buscar en
Revista de Psiquiatría y Salud Mental
Toda la web
Inicio Revista de Psiquiatría y Salud Mental Transient drop in the neutrophil count during COVID-19 regardless of clozapine t...
Información de la revista
Vol. 15. Núm. 2.
Páginas 134-137 (Abril - Junio 2022)
Descargar PDF
Más opciones de artículo
Vol. 15. Núm. 2.
Páginas 134-137 (Abril - Junio 2022)
Scientific letter
Acceso a texto completo
Transient drop in the neutrophil count during COVID-19 regardless of clozapine treatment in patients with mental illness
Disminución transitoria del recuento de neutrófilos durante COVID-19 independiente del tratamiento con clozapina en pacientes con esquizofrenia
Gabriel Vallecilloa,b,
Autor para correspondencia

Corresponding author.
, Josep Marti-Bonanya, Maria José Roblesc, Joan Ramón Fortunya, Fernando Lanaa, Victor Péreza,d
a Pischiatry Department, Emili Mira Healthcare Center, Parc de Salut Mar Consortium, Barcelona, Spain
b Addiction Research Group, Institut Hospital del Mar d’Investigacions Mèdiques, Parc de Salut Mar, Barcelona, Spain
c Geriatric Department Parc de Salut Mar, Consortium, Barcelona, Spain
d Mental Health Research Group, Institut Hospital del Mar d’Investigacions Mèdiques, Parc de Salut Mar, Barcelona, Spain
Este artículo ha recibido
Información del artículo
Texto completo
Descargar PDF
Figuras (1)
Texto completo
Research letter

People with mental health disorders are at increased risk for coronavirus disease 2019 (COVID-19) and its severe complications, including a high mortality rates, compared to the general population.1–5 In addition, the high prevalence of medical comorbidities in this population6 make the COVID-19 treatment more challenging and potentially less effective.7,8

In this sense, the use of clozapine, an atypical antipsychotic medication indicated for treatment-refractory schizophrenia9 has been associated to an increased susceptibility to COVID-19 infection compared with other antipsychotic medications.10 Moreover, prescribing clozapine requires close monitoring for serious adverse events, including agranulocytosis, myocarditis, aspiration pneumonia, and clozapine toxicity, as seizures, ileus and delirium,11,12 which could be higher in the setting of COVID-19, as clozapine plasma concentrations increase during acute systemic infection because of the CYP1A2 enzymes’ inhibition by cytokines,13 and the reduction or ceasing tobacco smoking in patients during acute illness.14

Owing to the risk of clozapine-associated severe neutropenia, absolute neutrophil count monitoring programs are a prerequisite for clozapine dispensation.11,12 Clozapine neutropenia appears usually in the first 18 weeks of treatment with progression to life-threatening agranulocytosis in a minority of patients (0.8%).11,12 However, during COVID-19 pandemic, some case series have reported a reduction in neutrophil count and severe neutropenia in patients on clozapine treatment, resulting in clozapine withdrawal.15–19 and raising the concern of clozapine toxicity in the setting of COVID-19.20,21 Nevertheless, these studies were case series and did not have a group control of patients without clozapine treatment to evaluate the effects of the medication or the infection on the neutrophil counts.

Therefore, the aims of study was to compare the neutrophil dynamics during COVID-19 between patients with mental illness according to the clozapine use.

This observational study was conducted at the Emili Mira Healthcare Center, a public acute and long-term psychiatric care center in Barcelona (Spain) with 300 places and dependent on a large tertiary teaching hospital.

People with mental illness on the basis of ICD-10, who had a positive determination of coronavirus SARS-CoV-2 real time reverse-transcription-polymerase chain reaction (cobas® SARS-CoV-2 Test Roche laboratories) in nasopharyngeal samples were included in the study. Patients with lack of data on hematological parameters during COVID-19 or suffering from hematological malignancies or immunodeficient states (excluding diabetes mellitus) or less than six months on stable psychiatric treatment were excluded from the study. Patients were identified from the database of the patients admitted in the center from March 2020 to February 2021.

For the purpose of the study, socio-demographic and clinical characteristics were extracted from the patients’ medical records and categorized to maintain anonymity where necessary.

The total leukocytes count, absolute neutrophil count and lymphocyte count were the registered hematological parameters. Baseline counts were considered those taken at least 30 days before a positive SARS-CoV-2 test; COVID-19 counts, those taken between the day of the positive SARS-CoV-2 test and seven days later; and post-COVID-19 count, those counts taken between seven and fourteen days before of positive SARS-CoV-2 test. Psychiatric polypharmacy was defined as the prescription of two or more psychiatric medications concurrently to a patient.

The main outcome of the study was the change of the neutrophil count during COVID-19, measured as the total difference between the baseline and COVID-19 count. The secondary objectives were the incidence of neutropenia, measured as a neutrophil count <1500cells/mcL and the change of neutrophil count during COVID-19 according to the use of clozapine treatment.

Descriptive statistics were expressed as median and interquartile range for quantitative variables and absolute frequencies and percentages for qualitative variables. Wilcoxon test was used to compare quantitative variables. Analysis were made using SPSS software, version 17.0.0 (Chicago, IL).

The study complied with the ethical statements in the Declaration of Helsinki (64th General Assembly, Fortaleza, Brazil, October 2013) and was approved by the local Institutional Review Board.

There were 69 patients admitted in the center who had COVID-19 during the study period. Thirty-eight patients were excluded for lack of hematological parameters. Finally, a total of 31 patients were included in the study.

Clinical characteristics of the patients are shown in Table 1. All patients had schizophrenia spectrum disorders, psychiatric polypharmacy and were on second-generation antipsychotic treatment. The main medical comorbidities were: obesity in 17 (54.8%) patients, hypertension in 11 (26.8%), chronic respiratory diseases in 8 (25.8%), diabetes in 6 (19.3%), chronic heart diseases in 3 (9.6%), and chronic kidney diseases in 3 (9.6%).

Table 1.

Clinical characteristics of 31 patients with mental illness and COVID-19 included in the study.

n  31 
Age1  55 (50–77) 
Men  22 (70.9%) 
Psychiatric diagnostic categories
Schizophrenia disorder  23 (74.2%) 
Deficit intellectual  6 (19.4%) 
Bipolar disorder  2 (6.4%) 
COVID-19 severity
Mild  24 (77.4%) 
Moderate  7 (22.6%) 
Antipsychotic treatment  31 (100%) 
>2 antipsychotic drugs  20 (64.5%) 
Clozapine treatment  16 (51.6%) 
Mood stabilizers treatment  8 (25.8%) 
Antidepressants treatment  8 (25.8%) 
Benzodiacepines treatment  19 (61.3%) 
Leukocyts1(cell/mcL)  7000 (4098–8120) 
Neutrophils1(cell/mcL)  4480 (2224–5160) 
Lymphocits1(cell/mcL)  2080 (1112–2375) 

Data are presented as Number. (%) unless otherwise indicated. 1: Data presented as mean±standard deviation. 2: Data presented as median and interquartile range.

Three quarter of patients had mild COVID-19 and two patients died.

Half of patients were on clozapine treatment with a median clozapine doses of 350 (IQR: 175–400) mg/day and baseline plasma concentration of 450 (IQR: 370–490) ng/mL. Median plasma concentrations at COVID-19 (available for 12 patients) were 604 (400–870) ng/mL and statistically significant (p 0.04) compared to baseline levels. Five patients had clozapine levels >600ng/mL requiring dose reduction.

Median blood parameters by time period are shown in Fig. 1. A significant decrease of total leukocytes (4510cells/mcL), absolute neutrophils (3000cells/mcL) and lymphocytes (1280cells/mcL) were observed at COVID-19 compared to baseline (p<0.01 for all comparisons). A significant increase of total leukocytes (7200cells/mcL, p<0.01), absolute neutrophils (4150cells/mcL, p<0.01) and lymphocytes (1705cells/mcL, p<0.03) at post-COVID-19 were observed compared to COVID-19 counts. There was not statistically significant differences between total leukocytes (p 0.85), absolute neutrophil (p 0.81) counts between baseline and post-COVID-19 counts, while lymphocyte was significant (p 0.05).

Figure 1.

Mean blood parameters by time period.


Median change of neutrophil count at COVID-19 was -560cells/mcL (IQR: −1510, −1160) representing a median percentage of −27.6% (IQR: −47%, −2%). There was not differences in median neutrophil change according to clozapine use; −680 (IQR: −1502, −145) cells/mcL for the clozapine group and −550 (IQR: −1805, −405) cells/mcL for the non-clozapine group (p 0.51).

Clinical characteristics of the three patients with neutropenia are shown in Table 2. Two patients received clozapine treatment and had previous neutropenia during clozapine titration. Clozapine treatment was temporally discontinued in one of them for decreasing neutrophil count to 100cells/mcL. After withdrawal of new medication introduced for the COVID-19 treatment, neutropenia was resolved.

Table 2.

Clinical characteristics of the three patients with neutropenia.

Age (years)  57  55  68 
Sex  Woman  Woman  Man 
Psychiatric diagnostic  Schizophrenia  Schizophrenia  Schizophrenia 
Clozapine use  Yes  Yes  No 
Baseline levels (ng/mL)  454  378  – 
COVID-19 levels (ng/mL)  850  587  – 
Severity COVID-19  Mild  Moderate  Mild 
Neutrophil count(cell/mcL)
Baseline  2390  2130  4500 
COVID-19  970  100  1300 
Post-COVID-19  1850  3150  5380 
Cause  Hydroxychloroquine  Metamizol  Ibuprophene 

The results observed in this study showed that during COVID-19 there was a transient drop fall in the neutrophil count in patients with mental illness, regardless of the type of second-generation antipsychotic treatment they received. In addition, cases of neutropenia were related to the introduction of new medications for the COVID-19 treatment.

Viral infections, including those caused by Epstein–Barr virus, cytomegalovirus, hepatitis A and B viruses, parvovirus, Influenzavirus species, measles and HIV, are a common cause of neutropenia, due either to bone marrow suppression or to peripheral destruction.22,23 In the case of COVID-19, lymphopenia followed by thrombopenia are the most usual hematological findings.24–28 However, alterations in neutrophils have also been reported and associated to the severity and progression of the disease; while a small fall of neutrophil counts has been observed in mild cases,28 an increased in neutrophil counts together a decrease in lymphocyte count has been considered a risk factor for Acute Respiratory Distress Syndrome during the disease course.24–28

Thus, the transitory neutrophil count drop observed in this study, which included mostly non-severe COVID-19 cases, is according to data observed in mild COVID-19 cases.28 This finding have several major implications. First, clozapine should generally be continued as the neutrophil count decrease seems to be a non-pathological event during mild COVID-19.28 However, close plasma concentration monitoring is advisable, as clozapine plasma concentrations increased during COVID-19 in this study, resulting in dose readjustment in five patients. The CYP1A2 enzymes’ inhibition by cytokines released during an infection and the reduction or ceasing tobacco smoking in patients during acute illness are well established risk factors that can increase clozapine plasma concentrations during COVID-19.13,14

Second, patients who experience neutropenia in the course of COVID-19 should be investigated and monitored as per routine clinical practice,29 as it cannot be assumed to be secondary to the viral infection or clozapine treatment. Nevertheless, other causes of drug-induced neutropenia30 should be evaluated, particularly medications used for the treatment of infection. In addition, it is interesting to note that the two patients with neutropenia had the antecedent of previous neutropenia during clozapine titration and a low baseline neutrophil, which could be used as a marker of future risk of neutropenia

Finally, it is important to evaluate the risk of drug-drug interactions of COVID-19 treatments to prevent the risk of clozapine toxicity; as some antiretrovirals, as lopinavir and darunavir, which were widely used during the first months of the pandemic without clinical efficacy against coronavirus SARS-CoV-2, are inhibitors of the cytochrome P45031.

The study had some limitations, namely the observational design and the small number of patients included. However, patient's clinical characteristics were well defined, including a stable antipsychotic treatment. These results should be confirmed in larger samples.

In conclusion, this study showed the relevance of a comprehensive clinical assessment of suspected COVID-19 infection in patients with mental illness, including evaluation for features of pneumonia, full blood count and risk of side effects of newly introduced treatments. In addition, clozapine treatment should be continued at least in mild cases, however, consideration should be given to dose reduction.

M. Taquet, S. Luciano, J.R. Geddes, P.J. Harrison.
Bidirectional associations between COVID-19 and psychiatric disorder: retrospective cohort studies of 62 354 COVID-19 cases in the USA.
Lancet Psychiatry, 8 (2021), pp. 130-140
S.W. Lee, J.M. Yang, S.Y. Moon, I.K. Yoo, E.K. Ha, S.Y. Kim, et al.
Association between mental illness and COVID-19 susceptibility and clinical outcomes in South Korea: a nationwide cohort study.
Lancet Psychiatry, 7 (2020), pp. 1025-1031
Q. Wang, R. Xu, N.D. Volkow.
Increased risk of COVID-19 infection and mortality in people with mental disorders: analysis from electronic health records in the United States.
World Psychiatry, 20 (2021), pp. 124-130
L. Li, F. Li, F. Fortunati, J.H. Krystal.
Association of a prior psychiatric diagnosis with mortality among hospitalized patients with Coronavirus Disease 2019 (COVID-19) infection.
JAMA Netw Open, 3 (2020), pp. e2023282
K. Nemani, C. Li, M. Olfson, E.M. Blessing, N. Razavian, J. Chen, et al.
Association of psychiatric disorders with mortality among patients with COVID-19.
JAMA Psychiatry, 27 (2021), pp. e204442
I. Šimunović Filipčić, I. Filipčić.
Schizophrenia and physical comorbidity.
Psychiatr Danub, 30 (2018), pp. 152-157
K. Nandy, A. Salunke, S.K. Pathak, A. Pandey, C. Doctor, K. Puj, et al.
Coronavirus disease (COVID-19): a systematic review and meta-analysis to evaluate the impact of various comorbidities on serious events.
Diabetes Metab Syndr, 14 (2020), pp. 1017-1025
N. Zaki, H. Alashwal, S. Ibrahim.
Association of hypertension, diabetes, stroke, cancer, kidney disease, and high-cholesterol with COVID-19 disease severity and fatality: a systematic review.
Diabetes Metab Syndr, 14 (2020), pp. 1133-1142
D. Siskind, L. McCartney, R. Goldschlager, S. Kisely.
Clozapine v. first- and second-generation antipsychotics in treatment-refractory schizophrenia: systematic review and meta-analysis.
Br J Psychiatry, 209 (2016), pp. 385-392
R. Govind, D. Fonseca de Freitas, M. Pritchard, R.D. Hayes, J.H. MacCabe.
Clozapine treatment and risk of COVID-19 infection: retrospective cohort study.
Br J Psychiatry, 27 (2020), pp. 1-7
D.D. Miller.
Review and management of clozapine side effects.
J Clin Psychiatry, 61 (2000), pp. 14-17
E. Iqbal, R. Govind, A. Romero, O. Dzahini, M. Broadbent, R. Stewart, et al.
The side effect profile of Clozapine in real world data of three large mental health hospitals.
PLOS ONE, 15 (2020), pp. e0243437
S.R. Clark, N.S. Warren, G. Kim, D. Jankowiak, K.O. Schubert, S. Kisely, et al.
Elevated clozapine levels associated with infection: a systematic review.
Schizophr Res, 192 (2018), pp. 50-56
E. Wagner, L. McMahon, P. Falkai, A. Hasan, D. Siskind.
Impact of smoking behavior on clozapine blood levels – a systematic review and meta-analysis.
Acta Psychiatr Scand, 142 (2020), pp. 456-466
T. Cranshaw, T. Harikumar.
COVID-19 infection may cause clozapine intoxication: case report and discussion.
Schizophr Bull, 46 (2020), pp. 751
S. Dotson, N. Hartvigsen, T. Wesner, T.J. Carbary, G. Fricchione, O. Freudenreich.
Clozapine toxicity in the setting of COVID-19.
Psychosomatics, 61 (2020), pp. 577-578
S. Bonaccorso, A. Ricciardi, S. Ouabbou, C. Theleritis, A. Ross-Michaelides, A. Metastasio, et al.
Clozapine, neutropenia and Covid-19: should clinicians be concerned? 3 months report.
Brain Behav Immun Health, 13 (2021), pp. 100212
S. Gee, D. Taylor.
COVID-19 infection causes a reduction in neutrophil counts in patients taking clozapine.
J Psychiatry Neurosci, 46 (2021), pp. E232-E237
M. Butler, F. Bano, M. Calcia, I. McMullen, C.C. Sin Fai Lam, L.J. Smith, et al.
Clozapine prescribing in COVID-19 positive medical inpatients: a case series.
Ther Adv Psychopharmacol, 10 (2020),
D. Siskind, W.G. Honer, S. Clark, C.U. Correll, A. Hasan, O. Howes, et al.
Consensus statement on the use of clozapine during the COVID-19 pandemic.
J Psychiatry Neurosci, 45 (2020), pp. 200061
S. Gee, F. Gaughran, J. MacCabe, S. Shergill, E. Whiskey, D. Taylor.
Management of clozapine treatment during the COVID-19 pandemic.
Ther Adv Psychopharmacol, 10 (2020),
N. Singh, S. Singh Lubana, L. Dabrowski.
Isolated chronic and transient neutropenia.
Cureus, 11 (2019), pp. e5616
I.E. Galani, E. Andreakos.
Neutrophils in viral infections: current concepts and caveats.
J Leukoc Biol, 98 (2015), pp. 557-564
E. Terpos, I. Ntanasis-Stathopoulos, I. Elalamy, E. Kastritis, T.N. Sergentanis, M. Politou, et al.
Hematological findings and complications of COVID-19.
Am J Hematol, 95 (2020), pp. 834-847
J.L. Frater, G. Zini, G. d’Onofrio, H.J. Rogers.
COVID-19 and the clinical hematology laboratory.
Int J Lab Hematol, 42 (2020), pp. 11-18
A. Ziadi, A. Hachimi, B. Admou, R. Hazime, I. Brahim, F. Douirek, et al.
Lymphopenia in critically ill COVID-19 patients: a predictor factor of severity and mortality.
Int J Lab Hematol, 43 (2021), pp. e38-e40
S. Lin, W. Mao, Q. Zou, S. Lu, S. Zheng.
Associations between hematological parameters and disease severity in patients with SARS-CoV-2 infection.
J Clin Lab Anal, 35 (2021), pp. e23604
A. Anurag, P.K. Jha, A. Kumar.
Differential white blood cell count in the COVID-19: a cross-sectional study of 148 patients.
Diabetes Metab Syndr, 14 (2020), pp. 2099-2102
J. Palmblad, C.C. Nilsson, P. Höglund, H.A. Papadaki.
How we diagnose and treat neutropenia in adults.
Expert Rev Hematol, 9 (2016), pp. 479-487
B.R. Curtis.
Non-chemotherapy drug-induced neutropenia: key points to manage the challenges.
Hematology Am Soc Hematol Educ Program, 2017 (2017), pp. 187-193
Copyright © 2021. SEP y SEPB
Opciones de artículo
es en pt

¿Es usted profesional sanitario apto para prescribir o dispensar medicamentos?

Are you a health professional able to prescribe or dispense drugs?

Você é um profissional de saúde habilitado a prescrever ou dispensar medicamentos

Quizás le interese:
No mostrar más